Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
523.58(c) 536.01(c) 537.92(c) 534.27(c) 534.02(c) Last
914 609 846 227 914 787 678 846 655 604 Volume
-0.74% +2.37% +0.36% -0.68% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12 139 M - -
Net income 2021 5 003 M - -
Net cash position 2021 10 664 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Sales 2022 11 280 M - -
Net income 2022 4 096 M - -
Net cash position 2022 12 040 M - -
P/E ratio 2022 13,9x
Yield 2022 -
Capitalization 55 301 M 55 301 M -
EV / Sales 2021 3,68x
EV / Sales 2022 3,84x
Nbr of Employees 9 447
Free-Float 82,2%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 08:00amPresentation
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
06/22REGENERON PHARMACEUTICALS  : to Participate in Guggenheim Biopharma Strategy Ser..
PR
06/21Dual-antibody drugs effective against COVID-19 variants in animal study
RE
06/21Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-..
RE
06/18BioNTech Doses First Patient in Mid-Stage Study of mRNA Cancer Vaccine
MT
06/18BIONTECH  : Doses First Patient in Phase 2 Trial of Vaccine Candidate in Patient..
MT
06/17REGENERON PHARMACEUTICALS  : Regen-cov phase 3 recovery trial meets primary outc..
AQ
06/17EMEA MORNING BRIEFING  : Fed's Surprise Hawkish -2-
DJ
06/16Healthcare Shares Slip but Beat the Broader Market -- Health Care Roundup
DJ
06/16REGENERON PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security H..
AQ
06/16REGENERON PHARMACEUTICALS  : Phase 3 Study Shows REGEN-COV Reduces Death Risk in..
MT
06/16STUDY : Antibody cocktail by Regeneron cuts COVID-19 death risk by 20%
AQ
06/16WALL STREET STOCK EXCHANGE : How yesterday’s data could affect Fed policy
06/16EUROPEAN MIDDAY BRIEFING  : Investors Pause With -2-
DJ
06/16ROCHE  : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage T..
MT
06/16REGENERON PHARMACEUTICALS  : Says REGEN-COV Improves Survival Rate in Hospitaliz..
MT
More news
News in other languages on REGENERON PHARMACEUTICALS
06/16WALL STREET STOCK EXCHANGE : Wall Street lager gesloten na rentebesluit Fed
06/16WALL STREET STOCK EXCHANGE : Wall Street koerst af op lager slot
06/16WALL STREET STOCK EXCHANGE : Cómo podrían afectar los datos de ayer a la polític..
06/16WALL STREET STOCK EXCHANGE : Verdeelde start Wall Street in de maak
06/16WALL STREET STOCK EXCHANGE : Futures wijzen op vlakke start Wall Street
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 534,02 $
Average target price 621,64 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS10.54%55 301
GILEAD SCIENCES, INC.15.09%84 469
WUXI APPTEC CO., LTD.24.70%66 143
BIONTECH SE190.10%54 605
VERTEX PHARMACEUTICALS-20.09%48 589
BEIGENE, LTD.28.69%30 138